NBIX•benzinga•
Morgan Stanley Assumes Neurocrine Biosciences at Overweight, Lowers Price Target of $150
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 7, 2025 by benzinga